



ASX ANNOUNCEMENT

Lumos Diagnostics Raises A\$2.65 Million In Successful Placement

Melbourne, VIC. (30th October 2023) - Lumos Diagnostics (ASX:LDX, “Lumos” or the “Company”) today announces it has raised A\$2.65 million (before costs) through a private placement of 37.9 million shares at A\$0.07 per share to existing institutional shareholders of the Company. The issue price represents 10% discount to the Company’s closing share price on Friday, 27 October 2023.

The Company will be utilising its remaining Placement Capacity under Listing Rule 7.1 and 7.1A on or around 2 November 2023.

The placement used Lumos’ remaining placement capacity to provide some additional working capital to support:

- existing pipeline of opportunities including FebriDx and ViraDx launch in the United States
- growing pipeline of new opportunities with existing strategic partners and potential new commercial partners

Given the relatively modest uptake by shareholders in the Share Placement Plan (SPP) that was completed in early August, the Company decided to offer its institutional shareholders the ability to take up the remaining placement capacity at the same price as the unsubscribed shares were offered to all shareholders in the SPP.

The Company looks forward to updating its shareholders further at Lumos’ Annual General Meeting that is scheduled to be held on Thursday, 2 November 2023.

This announcement was approved by the Lumos Disclosure Committee.

###

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or call +1 941-556-1850.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598